12 results about "Sphingolipid metabolism" patented technology

The invention provides a drug permeability clinical prediction model, a construction method thereof and a non-specific drug permeability evaluation method, and belongs to the technical field of biological medicine. The invention provides a construction method of a drug permeability clinical prediction model. According to the construction method, intestinal microorganism characteristics are introduced into model construction for the first time. The prediction performance of the constructed LGBM model containing the intestinal microorganism characteristics in the aspect of NAC permeability prediction is superior to that of other traditional business models. The invention also provides a serine-derived sphingolipid de novo synthesis pathway, which is different from the traditional sphingolipid de novo synthesis pathway, and is named as a cysteine sphingolipid metabolism pathway, NAC-derived cysteine may participate in the biosynthesis of microbial sphingolipid through covalent binding with palmitoyl-CoA, thereby damaging intestinal permeation of NAC.

The invention relates to the technical field of gene engineering, and relates to a construction method of sgRNA with a pBD2 gene knocked out and a construction method of a pig intestine epithelial cell line with the pBD2 gene knocked out. According to a pBD2 gene sequence, sgRNA capable of targeting the gene is designed and synthesized, plasmids of a CRISPR / Cas9 system containing the sgRNA are constructed by using a molecular cloning and recombination technology, the plasmids are transfected into a pig small intestine epithelial cell line, gene editing is performed on a specific position of the pBD2 gene, and a stable monoclonal cell line with the pBD2 gene knocked out is obtained through puromycin drug screening. The homozygous pBD2 gene knockout cell strain obtained by the method is used as a cell model and can be used for exploring the effects of the pBD2 gene in the aspects of immunoregulation, sphingolipid metabolism, cell cycle and the like of small intestine cells.

The present application provides a method for culturing CAR-T cells and its application in tumor treatment, belonging to the field of biomedical technology. Specifically, the method includes culturing CAR-T cells with sphingolipid metabolites. Culturing CAR-T cells with sphingolipid metabolites in vitro can significantly increase the killing efficiency of CAR-T cells, slow down the tumor growth rate, extend the survival period of patients / animals, and will not impose an additional metabolic burden on the body, with lower toxic and side effects. In addition, this method does not perform any modification on the cells themselves, thus reducing the unknown potential risks for patients / animals due to the reinfusion of various modified adjuvants, and therefore has higher safety.

Disclosed in the present invention are a sphingolipid metabolic marker, an analysis method therefor and a use thereof. The sphingolipid metabolic marker can be effectively used for early diagnosis, course monitoring and prognosis assessment of asthma, and has the advantages of high sensitivity, rapidness, convenience and accurate and reliable result. The sphingolipid metabolic marker at least comprises one of the following substances: galactosylceramide d18:1 / 16:0 and galactosylceramide d18:1 / 14:0.

A method and markers for identifying cold sensitivity of different peach varieties, which relates to the field of fruit preservation technologies. According to lipid metabolomics identification and big data analysis, compositions of sphingolipids in different peach varieties are extracted, common components of sphingolipids of different varieties are compared, so as to provide a method for identifying a CI process of different peach varieties based on sphingolipid metabolism.

The present invention provides the use of the combined use of bilirubin, chondroitin sulfate and licofelone in the preparation of a medicament for treating osteoarthritis. The present invention also provides a sequential targeted drug delivery system for treating arthritis, which is prepared from bilirubin, chondroitin sulfate and licofelone as raw materials, and the molar ratio of the bilirubin, chondroitin sulfate and licofelone is: 1-10 parts of bilirubin, 1-20 parts of chondroitin sulfate, and 0.1-5 parts of licofelone. The present invention also provides a preparation method and use of the sequential targeted drug delivery system. The present invention discovers for the first time the synthesis of chondroitin sulfate modified with bilirubin, and encapsulates licofelone through the self-assembled micelles of the polymer, thereby realizing sequential drug delivery, efficiently regulating the abnormal sphingolipid metabolism and AA metabolism of M1 macrophages, and thus converting them into M2 macrophages. In addition, the delivery system of the present invention can prolong the residence and action time of licofelone in the joint.

The invention relates to the technical field of drugs for treating hypertrophic scars, in particular to application of triglycosyl ceramide in treatment of hypertrophic scars. Based on a newly found molecular regulation mechanism, the heterogeneity of skin fibroblasts is regulated in a targeted manner, so that pathological fibrosis and scar formation in a burn wound healing process are effectively inhibited. The invention provides a strategy for accurately intervening the transdifferentiation of fibroblasts to myofibroblasts and promoting the fibrosis direction. In the prior art, an effective target spot aiming at a fibroblast heterogeneity key regulation and control node on a burn wound surface is lacked. The invention discloses a new'HEXB-Gb3-FGF2 'regulation axis, and develops a treatment method for specifically targeting a key product triglycosyl ceramide of glycosphingolipid metabolism.

The application of ceramide in the control of rice blast fungus falls within the field of biological control. This invention relates to the application of ceramide in the control of rice blast fungus: a combination of ceramide and lipopeptides is used for the control of rice blast fungus. Exogenous addition of ceramide significantly enhances the stress effect of lipopeptides on rice blast fungus. It also enhances the abnormal accumulation of glycogen and lipid droplets in conidia, promotes the bursting of ROS, and increases intracellular ceramide and calcium... 2+ The invention increases the content of malondialdehyde (MDA) in mycelium, enhances membrane lipid peroxidation, and decreases ergosterol content. Furthermore, it inhibits the expression of ergosterol synthesis genes, UPR target genes, and sphingolipid metabolism-related genes. This invention develops a highly efficient natural agent against rice blast by combining exogenous Cer with lipopeptides. This agent effectively reduces the pathogenicity of rice blast fungus and significantly inhibits its infection of rice, laying the foundation for the development of novel biological control agents.

The present disclosure pertains to the use of an Anc80 viral vector that encodes a sphingolipid-metabolizing protein such as acid ceramidase to achieve expression of the sphingolipid-metabolizing protein in a mammalian cell or group of cells. Expression of the protein from the Anc80 vector reduces high levels of ceramide in the cell that lead to cell death or senescence.

The invention provides a CAR-T cell culture method and application of the CAR-T cell culture method in tumor treatment, and belongs to the technical field of biological medicine. Specifically, the method comprises the step of performing culture treatment on the CAR-T cells by adopting sphingolipid metabolites. The in-vitro culture treatment is carried out on the CAR-T cells by adopting the sphingolipid metabolite, so that the killing efficiency of the CAR-T cells can be remarkably improved, the growth speed of tumors can be slowed down, the lifetime of patients / animals can be prolonged, no extra metabolic burden is generated on the body, and the toxic and side effects are lower. In addition, the method does not carry out any modification on the cells, so that the unknown potential risk increased by the patient / animal due to the feedback of various modification adjuvants is reduced, and the safety is higher.

The invention provides a pharmaceutical composition and application thereof, and belongs to the technical field of biological medicine. The sphingolipid metabolite is added in the immune cell in-vitro culture process, the immune cell function is remodeled in a metabolic regulation mode, and the dryness and tumor killing capacity of the immune cells are remarkably enhanced.

The invention belongs to the technical field of medical biology, and particularly relates to an ALS mouse model constructed based on Sptlc-E260K point mutation and a construction method and application of the ALS mouse model. According to the Sptlc2-E260K point mutation mouse, key enzyme SPTLC2 is synthesized through targeted sphingolipid, functional mutation E260K is directly introduced, a sphingolipid metabolism pathway is abnormal, and the core pathology of sphingolipid metabolism imbalance in children type ALS is accurately simulated. Compared with SOD1 and TDP43 models, the invention fills up the blank of the existing model in the study of ALS related to sphingolipid metabolism, and provides a specific tool for exploring a neurodegenerative mechanism driven by abnormal metabolism. The method has the advantages that efficient identification is realized through selection of SPTLC2 gene targets and introduction of codon replacement and restriction enzyme cutting sites, so that the problem of incomplete pathological coverage caused by limitation of gene functions in the prior art is solved.